KCT0004562招募中未知
Multi-hospital, exploratory clinical trial for evaluating the efficacy and safety of edema relief and leg pain reduction effect in the treatment using Intermittent pneumatic Compression for patients with edema pain in daily life
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Adult men and women over 19 years old
- •2) Those who have leg pain due to edema in their daily life
- •3) A person who fully understands the purpose and procedure of the research and wishes to participate in the clinical research through voluntary consent.
排除标准
- •1) Those who do not meet the age standard
- •2) Those who complain of numbness
- •3) Those who have had lower extremity surgery within the last 6 months
- •4) The person in charge who deems it inappropriate for participation in the test
研究者
相似试验
招募中
不适用
Multi-center, Investigator-initiated trial for evaluating the efficacy and safety of D+storm stentKCT0005532Ajou University Hospital200
已完成
2 期
Evaluation of Vascular Electrical Stimulation Therapy on Vaso-Occlusive crises in sickle cell patients.PACTR201907740118144Diavein SAS30
进行中（未招募）
1 期
An open-label, multicenter, follow-up trial to evaluate long-term safety and efficacy ofucb 34714 used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from partial onset seizuresEpilepsy - refractory Partial Onset SeizureMedDRA version: 8.0Level: LLTClassification code 10061334EUCTR2004-002140-10-ESCB S.A. Pharma Sector1,000
进行中（未招募）
1 期
An open-label, multicenter, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy.EpilepsyEUCTR2004-002140-10-GBCB S.A.853
进行中（未招募）
1 期
An open-label, multicenter, follow-up trial to evaluate long-term safety and efficacy of brivaracetam ucb 34714 used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy. - NDMedDRA version: 9.1 Level: LLT Classification code 10053551 Term: Intractable epilepsyEpilepsyEUCTR2004-002140-10-ITCB S.A. Casa Madre1,000